Maze Therapeutics (MAZE) Current Leases (2024 - 2026)

Maze Therapeutics has disclosed Current Leases across 3 years of filings, most recently posting $4.8 million for Q1 2026.

• Current Leases for Q1 2026 came in at $4.8 million, up 3.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (up 3.51% YoY), and the FY2025 annual result was $4.8 million, up 3.52% from the prior year.
• Current Leases came in at $4.8 million for Q1 2026 at Maze Therapeutics, up from $4.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $4.8 million in Q1 2026 to a low of $4.6 million in Q4 2024.
• The 3-year median for Current Leases is $4.7 million (2025), against an average of $4.7 million.
• Across the five-year window, Current Leases climbed 3.52% in 2025 and gained 3.51% in 2026, its largest moves.
• Maze Therapeutics' Current Leases stood at $4.6 million in 2024, then advanced by 3.52% to $4.8 million in 2025, then grew by 0.9% to $4.8 million in 2026.
• The last three Current Leases figures came in at $4.8 million (Q1 2026), $4.8 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.